uniQure N.V. (QUREN.MX)

Compare

325.95

+1.46

+(0.45%)

At close: December 11 at 10:12:13 AM CST

uniQure Full Year 2024 Earnings: Misses Expectations

uniQure ( NASDAQ:QURE ) Full Year 2024 Results Key Financial Results Revenue: US$27.1m (up 71% from FY 2023). Net loss...

Simply Wall St. last month

QURE
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington’s disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~ ~ Completed patient enrollment in the third cohort of the Phase I/II study of AMT-130 ~ ~ Initiated dosing of the Phase I/II study of AMT-260 in mesial temporal lobe epilepsy (mTLE); Implementing protocol changes to expand study inclusion criteria ~ ~

GlobeNewswire last month

QURE
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

Key Insights Given the large stake in the stock by institutions, uniQure's stock price might be vulnerable to their...

Simply Wall St. last month

QURE
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B. In an oral presentation at the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), data showed that through four years, HEMGENIX continues to deliver elevated and sustained factor I

PR Newswire last month

CMXHF

CSLLY

QURE
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of second dose cohort in the first quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of enrollment in the first cohort of the Phase I/

GlobeNewswire 2 months ago

QURE
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Jan. 30, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Independent Data Monitoring Committee (IDM

GlobeNewswire 2 months ago

QURE
uniQure Announces Pricing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by

GlobeNewswire 2 months ago

QURE
uniQure Announces Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purch

GlobeNewswire 2 months ago

QURE
uniQure price target raised to $32 from $12 at Stifel

Stifel analyst Paul Matteis raised the firm’s price target on uniQure (QURE) to $32 from $12 and keeps a Buy rating on the shares. The firm is “compelled” by the already developing efficacy signal/trends at 24-months where uniQure got alignment with the FDA and continuing RMAT plus CBER tailwinds, which it thinks make the set up “bullish” as uniQure moves towards filing a BLA, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan

TipRanks 3 months ago

QURE
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate. During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has legs that can propel it further in 2025.

Motley Fool 3 months ago

QURE
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment.

Investor's Business Daily 3 months ago

PTCT

QURE
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE)

GlobeNewswire 3 months ago

QURE
Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?

Key Insights uniQure's estimated fair value is US$12.16 based on 2 Stage Free Cash Flow to Equity uniQure's US$7.45...

Simply Wall St. 3 months ago

QURE
$uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy$

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE). “The dosing of the first patient in our Phase I/II trial in temporal lobe epilepsy represents an important milestone for un

GlobeNewswire 4 months ago

QURE
What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates

Market forces rained on the parade of uniQure N.V. ( NASDAQ:QURE ) shareholders today, when the analysts downgraded...

Simply Wall St. 4 months ago

QURE
uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

uniQure ( NASDAQ:QURE ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.29m (up 63% from 3Q 2023). Net...

Simply Wall St. 4 months ago

QURE
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~ Presented positive interim data from Phase I/II trial of AMT-130 demonstrating slowing of Huntington’s disease progression and reductions in key biomarker of neurodegeneration ~ ~ Initiated patient dosing in new Phase I/II studies of AMT-162 in SOD1-ALS and AMT-191 in Fabry disease; First patient enrolle

GlobeNewswire 4 months ago

QURE
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1), a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-cent

GlobeNewswire 5 months ago

QURE
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1), a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-cent

GlobeNewswire 5 months ago

QURE
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure’s investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.

GlobeNewswire 6 months ago

QURE

Performance Overview

Return	QUREN.MX	MSCI WORLD (^990100-USD-STRD)
YTD	0.00%	-10.29%
1-Year	0.00%	-2.24%
3-Year	-1.97%	+10.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

uniQure N.V. (QUREN.MX)

uniQure Full Year 2024 Earnings: Misses Expectations

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure price target raised to $32 from $12 at Stifel

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates

uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

Performance Overview